![Kawasaki Dis Canada su Twitter: Kawasaki Dis Canada su Twitter:](https://pbs.twimg.com/media/DTsbaGDXcAAS9HL.png)
Kawasaki Dis Canada su Twitter: "Approximately 10% to 20% of patients with Kawasaki disease develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution
Cumulative recurrence rates of Kawasaki disease calculated by different... | Download Scientific Diagram
![The Epidemiology and Clinical Features of Kawasaki Disease in Australia | American Academy of Pediatrics The Epidemiology and Clinical Features of Kawasaki Disease in Australia | American Academy of Pediatrics](https://pediatrics.aappublications.org/content/pediatrics/133/4/e1009/F1.large.jpg)
The Epidemiology and Clinical Features of Kawasaki Disease in Australia | American Academy of Pediatrics
![Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5d113c51-9037-44ef-bf21-ef221a51cd49/gr1.gif)
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Recurrent lip swelling as a late presentation of kawasaki disease.pdf | Clinical Medicine | Medical Specialties
![Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/42b7004d-c481-405d-8d94-441838b60ddf/jah32384-fig-0001.gif)